Please find enclosed herewith Integrated Annual Report FY 2025-26 under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

August 11, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Submission of Integrated Annual Report under Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the Integrated Annual Report for the Financial Year 2025-26. The Annual Report is being sent through electronic mode to all those members whose e-mail ids have been registered with the Company/ Depository Participant/ Registrar and Transfer Agent and the same is also being made available on the website of the Company, at: www.alivus.com. Further, in accordance with the Regulation 36(1)(b) of the SEBI Listing Regulations, the Company has initiated sending a letter to the Shareholders whose e-mail ids are not registered with the Company/RTA/DPs, providing a web-link from where the Annual Report can be accessed on the website of the Company. Request you to kindly take the same on record. Thanking you Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing,O ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri E(), Mumbai– 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com B r e a d th E x p a n d i n g De th To Enhance Leveraging Adjacencies 62-5202 tropeR launnA detargetnI Table of Contents About the Report Performance We are pleased to present the fourth Integrated Report of Dashboard Alivus Life Sciences Limited ('Alivus'), formerly Glenmark Life Sciences Limited, for the financial year 2025–26 (FY26). Prepared in accordance with the Integrated Reporting Framework, this report provides a holistic view of our Message from strategy, governance, performance and outlook, and how the Chairman these collectively contribute to long-term value creation. Our reporting is guided by integrated thinking, reflecting the interconnected role of the six capitals: Financial, Manufactured, Intellectual, Human, Social & Relationship, Message from and Natural, in driving sustainable business performance. B r e a d t h 07 the MD & CEO Through this approach, we seek to present a balanced E x p a n d i n g perspective on the opportunities, risks and capabilities that shape our ability to create value for stakeholders over the short, medium and long term. Company 09 Overview The report is structured around our value creation model, De th illustrating how we transform key inputs into measurable To Enhance 09 Ÿ About Alivus business outcomes. Performance across the six capitals is supported by relevant qualitative and quantitative 13 Ÿ Awards & Recognition indicators, providing a concise, transparent and connected 14 Ÿ Global Footprint account of our progress during the year. Scope and Boundary Governance This report covers the financial and non-financial At Alivus, while we actively pursue This is the essence of Leveraging Adjacencies. performance of Alivus Life Sciences Limited for the period growth opportunities in what we We are expanding into areas that complement our Value Creation from April 1, 2025, to March 31, 2026, in line with our are known for, we believe exciting capabilities and strengthen our existing platform. annual reporting cycle. Details of our shareholding pattern growth opportunities also reside These adjacencies allow us to create stronger 21 Model are presented in the Corporate Governance section. There in what we know. linkages across the pharmaceutical value chain have been no financial restatements of historical information and unlock greater synergies across our business. during the reporting period. Over the years, we have built More importantly, they enable us to become deep expertise in chemistry, Performance increasingly valuable and even more relevant to Reporting Standards and Frameworks manufacturing excellence and our customers by bringing together more of what 23 Ÿ Financial Capital This Integrated Report has been prepared with reference to process capabilities that extend far they need within a trusted relationship. beyond our existing portfolio. 27 Ÿ Manufactured CapitaI the Integrated Reporting Framework and Global Reporting 33 Ÿ Intellectual Capital Initiative (‘GRI’) standards, 2021. It also draws reference Our strategy is centred on unlocking As these connections grow, 37 Ÿ Human Capital from the United Nations Sustainable Development Goals greater value from this accumulated so does the depth of our business. (UN SDGs) and incorporates relevant requirements of the 44 Ÿ Social and Relationship Capital knowledge. Expertise that once National Voluntary Guidelines (NVGs) on Social, Our portfolio becomes richer, our 54 Ÿ Natural Capital Environmental and Economic Responsibilities of Business. enabled us to develop products is now being leveraged to create offerings become more integrated, The financial and statutory information presented in this adjacent business offerings, allowing our growth opportunities become Statutory Report report complies with the Companies Act, 2013, Indian us to broaden our portfolio while 60 larger and our customer Accounting Standards (Ind AS), the Securities and Exchange remaining firmly anchored to our 60 Ÿ Management Discussion and Analysis Board of India LODR (Listing Obligations and Disclosure core strengths. relationships become deeper. Requirements) Regulations, 2015, and other applicable 78 Ÿ Board’s Report statutory requirements. 99 Ÿ Business Responsibility and Sustainability Report The Company obtained independent limited assurance from 164 Ÿ Report on Corporate Governance the British Standards Institution (BSI) for its BRSR Core KPIs for FY 2025-26. The assurance statement is presented in the relevant section of the Integrated Report. Financial Statements Performance Dashboard FINANCIAL Revenue from Operations (in INR Mn) 25,518 up 6.9% 232,12 FY22 FY23 FY24 FY25 FY26 RNI( 216,12 238,22 968,32 815,52 36.53 FY22 FY23 FY24 FY25 FY26 )RNI( 11.83 34.83 36.93 99.54 EBITDA EPS (in INR Mn) (in INR) 8,577 45.99 up 19.6% up 16.1% 803,6 FY22 FY23 FY24 FY25 FY26 RNI( 217,6 368,6 271,7 775,8 (EBITDA Margin) 33.6% 31.4% 31.1% 30.0% 30.1% FY22 FY23 FY24 FY25 FY26 ROICE 679,5 FY22 FY23 FY24 FY25 FY26 RNI( 060,3 531,4 519,3 456,5 Net Cash Generated from Operating Activities (in INR Mn) 781,4 FY22 FY23 FY24 FY25 FY26 RNI( 076,4 907,4 758,4 546,5 01 02 Integrated Alivus Annual Report Life Sciences 2025-2026 Limited (in INR Mn) 5,645 5,654 PAT Margin 22.1 (PAT Margin) 22.1% 21.6% 20.6% 20.3% 19.7% Income Statement in INR Mn Balance Sheet in INR Mn FY26 FY25 FY24 FY23 FY22 FY26 FY25 FY24 FY23 FY22 Revenue from Operations 25,518 23,869 22,832 21,612 21,232 Total Equity 33,321 28,174 23,323 21,382 20,543 EBITDA for the year 8,577 7,172 6,863 6,712 6,308 Tangible Fixed Assets 12,914 10,369 8,962 8,242 6,763 Profit for the year 5,645 4,857 4,709 4,670 4,187 Cash and Cash Equivalents 7,824 5,487 3,014 2,838 5,122 Basic EPS (in INR) 45.99 39.63 38.43 38.11 35.63 Total Debt - - - - - 03 04 Integrated Alivus Annual Report Life Sciences 2025-2026 Limited Performance Dashboard NON-FINANCIAL PRODUCTS 50 1,85,809 63,805 176 DMFs and CEPs KL People filed across major markets water recycled & reused. benefited through the during FY26 taking the Up by 48.89% compared to FY25. newly introduced mobile unit Unique APIs cumulativ [Showing first 8,000 characters — download PDF for full document]